I

Immuneering Corp
NASDAQ:IMRX

Watchlist Manager
Immuneering Corp
NASDAQ:IMRX
Watchlist
Price: 1.83 USD -3.68% Market Closed
Market Cap: 54.3m USD
Have any thoughts about
Immuneering Corp?
Write Note

Intrinsic Value

IMRX's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

The intrinsic value of one IMRX stock under the Base Case scenario is 2.89 USD. Compared to the current market price of 1.83 USD, Immuneering Corp is Undervalued by 37%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

IMRX Intrinsic Value
2.89 USD
Undervaluation 37%
Intrinsic Value
Price
I
Worst Case
Base Case
Best Case

Valuation Backtest
Immuneering Corp

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for IMRX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about IMRX?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Immuneering Corp

Provide an overview of the primary business activities
of Immuneering Corp.

What unique competitive advantages
does Immuneering Corp hold over its rivals?

What risks and challenges
does Immuneering Corp face in the near future?

Has there been any significant insider trading activity
in Immuneering Corp recently?

Summarize the latest earnings call
of Immuneering Corp.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Immuneering Corp.

Provide P/S
for Immuneering Corp.

Provide P/E
for Immuneering Corp.

Provide P/OCF
for Immuneering Corp.

Provide P/FCFE
for Immuneering Corp.

Provide P/B
for Immuneering Corp.

Provide EV/S
for Immuneering Corp.

Provide EV/GP
for Immuneering Corp.

Provide EV/EBITDA
for Immuneering Corp.

Provide EV/EBIT
for Immuneering Corp.

Provide EV/OCF
for Immuneering Corp.

Provide EV/FCFF
for Immuneering Corp.

Provide EV/IC
for Immuneering Corp.

Show me price targets
for Immuneering Corp made by professional analysts.

What are the Revenue projections
for Immuneering Corp?

How accurate were the past Revenue estimates
for Immuneering Corp?

What are the Net Income projections
for Immuneering Corp?

How accurate were the past Net Income estimates
for Immuneering Corp?

What are the EPS projections
for Immuneering Corp?

How accurate were the past EPS estimates
for Immuneering Corp?

What are the EBIT projections
for Immuneering Corp?

How accurate were the past EBIT estimates
for Immuneering Corp?

Compare the revenue forecasts
for Immuneering Corp with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Immuneering Corp and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Immuneering Corp against its competitors.

Analyze the profit margins
(gross, operating, and net) of Immuneering Corp compared to its peers.

Compare the P/E ratios
of Immuneering Corp against its peers.

Discuss the investment returns and shareholder value creation
comparing Immuneering Corp with its peers.

Analyze the financial leverage
of Immuneering Corp compared to its main competitors.

Show all profitability ratios
for Immuneering Corp.

Provide ROE
for Immuneering Corp.

Provide ROA
for Immuneering Corp.

Provide ROIC
for Immuneering Corp.

Provide ROCE
for Immuneering Corp.

Provide Gross Margin
for Immuneering Corp.

Provide Operating Margin
for Immuneering Corp.

Provide Net Margin
for Immuneering Corp.

Provide FCF Margin
for Immuneering Corp.

Show all solvency ratios
for Immuneering Corp.

Provide D/E Ratio
for Immuneering Corp.

Provide D/A Ratio
for Immuneering Corp.

Provide Interest Coverage Ratio
for Immuneering Corp.

Provide Altman Z-Score Ratio
for Immuneering Corp.

Provide Quick Ratio
for Immuneering Corp.

Provide Current Ratio
for Immuneering Corp.

Provide Cash Ratio
for Immuneering Corp.

What is the historical Revenue growth
over the last 5 years for Immuneering Corp?

What is the historical Net Income growth
over the last 5 years for Immuneering Corp?

What is the current Free Cash Flow
of Immuneering Corp?

Discuss the annual earnings per share (EPS)
trend over the past five years for Immuneering Corp.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Immuneering Corp

Current Assets 89.1m
Cash & Short-Term Investments 85.7m
Other Current Assets 3.4m
Non-Current Assets 13.5m
PP&E 5.4m
Intangibles 7.1m
Other Non-Current Assets 1m
Current Liabilities 7.8m
Accounts Payable 2.1m
Accrued Liabilities 5.5m
Other Current Liabilities 259.8k
Non-Current Liabilities 4.2m
Other Non-Current Liabilities 4.2m
Efficiency

Earnings Waterfall
Immuneering Corp

Revenue
0 USD
Operating Expenses
-58.4m USD
Operating Income
-58.4m USD
Other Expenses
4.9m USD
Net Income
-53.5m USD

Free Cash Flow Analysis
Immuneering Corp

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

IMRX Profitability Score
Profitability Due Diligence

Immuneering Corp's profitability score is 15/100. The higher the profitability score, the more profitable the company is.

15/100
Profitability
Score

Immuneering Corp's profitability score is 15/100. The higher the profitability score, the more profitable the company is.

IMRX Solvency Score
Solvency Due Diligence

Immuneering Corp's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Immuneering Corp's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

IMRX Price Targets Summary
Immuneering Corp

Wall Street analysts forecast IMRX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for IMRX is 11.44 USD with a low forecast of 1.52 USD and a high forecast of 26.25 USD.

Lowest
Price Target
1.52 USD
17% Downside
Average
Price Target
11.44 USD
525% Upside
Highest
Price Target
26.25 USD
1 334% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for IMRX?

Click here to dive deeper.

Dividends

Immuneering Corp
does not pay dividends
Shareholder Yield

Current shareholder yield for IMRX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

IMRX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Immuneering Corp

Country

United States of America

Industry

Biotechnology

Market Cap

53.6m USD

Dividend Yield

0%

Description

Immuneering Corp. engages in the development of new medicines which are unlikely to be found by traditional drug discovery methods. The company is headquartered in Cambridge, Massachusetts and currently employs 64 full-time employees. The company went IPO on 2021-07-30. The firm is focused on improving patient outcomes by advancing a pipeline of oncology and neuroscience product candidates developed using its translational bioinformatics platform. Its development programs in oncology are focused on providing treatments for patients with solid tumors caused by mutations of the MAPK and mTOR pathways. Its lead product candidate, IMM-1-104, is designed to be a selective dual-MEK inhibitor that further disrupts KSR for the treatment of advanced solid tumors in patients harboring RAS mutant tumors. The firm's oncology programs target mutations of the RAS/RAF/MEK/ERK, (MAPK) and the PI3K/AKT/mTOR (mTOR), pathways. Its oncology programs include Dual-MEK: IMM-1-104, MEK-io, Trifecta-MEK, KRAS4B, RAS Induction, Covalent-MEK, and PI3K-alpha. The firm's neuroscience pipeline on Alzheimer's Disease (AD). Its neuroscience programs include IMM-ALL-01 and IMM-ALL-03.

Contact

MASSACHUSETTS
Cambridge
245 Main Street, Second Floor
+16175008080.0
immuneering.com

IPO

2021-07-30

Employees

64

Officers

Co-Founder, President, CEO & Director
Dr. Benjamin J. Zeskind M.B.A., Ph.D.
Co-Founder & Chair Emeritus
Mr. Robert J. Carpenter M.B.A., M.S.
Chief Scientific Officer
Dr. Brett M. Hall Ph.D.
Chief Business Officer
Mr. Harold E. Brakewood
Principal Financial & Accounting Officer, Chief Accounting Officer and Treasurer
Ms. Mallory Morales CPA
Director of Accounting & Operations and Assistant Corporate Controller
Ms. Paula George CPA
Show More
Chief Legal Officer & Secretary
Mr. Michael D. Bookman J.D.
Chief People Officer
Ms. Leah R. Neufeld
Head of Discovery & VP
Dr. Peter King Ph.D.
Head of Translational Pharmacology & VP
Dr. Praveen Nair Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one IMRX stock?

The intrinsic value of one IMRX stock under the Base Case scenario is 2.89 USD.

Is IMRX stock undervalued or overvalued?

Compared to the current market price of 1.83 USD, Immuneering Corp is Undervalued by 37%.

Back to Top